No Cover Image

Journal article 383 views 113 downloads

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

Alison Birtle, Mark Johnson, John Chester, Robert Jones, David Dolling, Richard T Bryan, Christopher Harris, Andrew Winterbottom, Anthony Blacker, James W F Catto, Prabir Chakraborti, Jenny L Donovan, Paul Anthony Elliott, Ann French, Satinder Jagdev, Benjamin Jenkins, Francis Xavier Keeley, Roger Kockelbergh, Thomas Powles, John Wagstaff, Caroline Wilson, Rachel Todd, Rebecca Lewis, Emma Hall

The Lancet, Volume: 395, Issue: 10232, Pages: 1268 - 1277

Swansea University Author: John Wagstaff

  • 53807.pdf

    PDF | Version of Record

    Released under the terms of a Creative Commons Attribution NonCommercial NoDerivs License (CC-BY-NC-ND).

    Download (594.34KB)

Check full text

DOI (Published version): 10.1016/s0140-6736(20)30415-3

Abstract

This paper reports the results of an open label phase III trial of Chemotherapy with platinum based chemotherapy versus observation in patients who had undergone nephrectomy for a transitional carcinoma of the upper urinary tract. Patients received four cycles of cisplatin/carboplatin at three weekl...

Full description

Published in: The Lancet
ISSN: 0140-6736
Published: Elsevier BV 2020
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa53807
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: This paper reports the results of an open label phase III trial of Chemotherapy with platinum based chemotherapy versus observation in patients who had undergone nephrectomy for a transitional carcinoma of the upper urinary tract. Patients received four cycles of cisplatin/carboplatin at three weekly intervals. 261 patients were randomised from 71 centres across the United Kingdom. At a median follow-up of 30.3 months chemotherapy significantly improved disease-free survival (hazard ratio 0·45, 95% CI 0·30–0·68; p=0·0001). Three year event free estimates were 71 and 46% for chemotherapy and observation respectively. 55 (43%) of patients given chemotherapy had grade 3 adverse events whilst 5 of 129 (4%) subjected to observation had grade 3 adverse events. Platinum based chemotherapy given within 90 days of nephrouretectomy significantly improved disease-free survival and should be offered to patients as a standard of care.
Issue: 10232
Start Page: 1268
End Page: 1277

Similar Items